07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Activiomics management update

Activiomics Ltd. , London, U.K.   Business: Supply/Service   Hired: Kevin FitzGerald as CEO, formerly CEO of F-star GmbH  ...
00:47 , Oct 1, 2013 |  BC Extra  |  Company News

Activiomics names FitzGerald CEO

Activiomics Ltd. (London, U.K.) named Kevin FitzGerald as CEO. FitzGerald was formerly CEO of F-star GmbH (Vienna, Austria). Activiomics is using its Targeted In-depth Quantification of Cell Signaling (TIQUAS) label-free proteomics software to identify prognostic...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Activiomics, Kyowa Hakko Kirin deal

Activiomics extended a 2012 deal with Kyowa under which Activiomics is using its Targeted In-depth Quantification of Cell Signaling (TIQUAS) phosphoproteomics platform to identify signaling mechanisms of lead compounds from Kyowa in cell-based systems. The...
07:00 , Mar 18, 2013 |  BioCentury  |  Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Activiomics, Kyowa Hakko Kirin deal

Activiomics will use its Targeted In-depth Quantification of Cell Signaling (TIQUAS) mass spectrometry technology to identify signaling mechanisms of lead compounds from Kyowa. The deal is part of a July deal between Activiomics and the...
07:00 , Jul 2, 2012 |  BioCentury  |  Emerging Company Profile

Activiomics: Unlabeled proteomics

Most proteomics platforms that rely on labeling can only be used in cell lines and handle a small number of samples in any one experiment, making it difficult to quantify significant changes in cell signaling....
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Activiomics board of directors update

Activiomics Ltd. , London, U.K.   Business: Supply/Service   Appointed: Trevor Nicholls, CEO of CABI, as non-executive chairman  ...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Financial News

Activiomics completes venture financing

Activiomics Ltd. , London, U.K.   Business: Supply/Service   Date completed: 3/14/11   Type: Venture financing   Raised: £500,000 ($802,450)   Investors: IP Group; IP Venture Fund; Company management  ...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Company News

Activiomics, UCB deal

Activiomics will use its Targeted In-depth Quantification of Cell Signaling (TIQUAS) mass spectrometry technology to identify signaling mechanisms for antibodies from UCB. The antibodies are in development for an undisclosed inflammatory indication. Activiomics will receive...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

GlaxoSmithKline, Institute of Cancer at Barts, Queen Mary, University of London proteomics, inflammation news

The institute and the university spun out their cell signaling pathway technology into newco Activiomics Ltd. Activiomics will use its Targeted In-depth Quantification of Cell Signalling (TIQUAS) mass spectrometry platform to quantify phosphopeptides for biomarker...